Become a Creator today!Start creating today - Share your story with the world!
Start for free
00:00:00
00:00:01
Embedding Clinical Research In Healthcare | Javara CEO Jennifer Byrne
24 Plays1 month ago
Today's guest is Jennifer Byrne, a veteran clinical research leader and CEO of Javara, an integrated research organization that has raised over $100 million to modernize how clinical trials are run inside health systems.
Drawing on nearly three decades of experience, Jennifer explains why clinical trials remain largely invisible to patients and clinicians, despite being central to drug and device development. The conversation unpacks how changes in healthcare delivery, increasing trial complexity, and physician burnout have made access to research harder rather than easier. We also explore why patient recruitment isn’t just a technology problem, but a question of trust, infrastructure, and incentives. Ultimately, this episode reframes clinical trials not as a niche research activity, but as a core part of public health, and a test of whether innovation in medicine is truly accessible.
Recommended
Transcript
Introduction to Healthcare Theory Podcast
00:00:00
Speaker
Welcome to the Healthcare Theory Podcast. I'm your host, Nikhil Reddy, and every week we interview the entrepreneurs and thought leaders behind the future of healthcare care to see what's gone wrong with our system and how we can fix it.
Why Discuss Clinical Trials?
00:00:15
Speaker
Today's topic is something that we often come to touch with but don't know too much about. Clinical trials sit at the center of how new drugs and devices reach patients. And yet, for something that touches nearly every part of healthcare, care the system behind them is largely invisible, incredibly complex, and often misunderstood.
Meet Jennifer Byrne, Advocate for Embedded Research
00:00:32
Speaker
So today's guest has spent nearly three decades inside that system. Jennifer Byrne began her career as a clinical research coordinator, oversaw clinical research operations across health systems, and now serves as the founder and CEO of Javara, a company that's raised millions in dollars to build an integrated research organization built her around a simple but powerful idea that clinical research should be embedded directly into the health systems that they work with, not bolted on as an afterthought.
00:00:59
Speaker
So
Jennifer's Journey into Clinical Research
00:01:00
Speaker
hi, Jennifer. Thank you for coming on today and welcome to The Healthcare care Theory. Hi, Nikhil. Good morning and excited to be here. Of course, super excited. And you've worked a lot of different positions within healthcare and within the clinical research space. And I think oftentimes people wind up there, but i'd love to hear what kept you in clinical trials and clinical research roles, your career like, and what was a motivating factor that's kept you in this space for a few decades now? um Yeah, Nikhil. So it's interesting. i like most of my clinical research colleagues really fell into this as a profession.
00:01:36
Speaker
um you know Going back to the late 80s when I was graduating from college, um you know at no point in time during my educational you know journey did anybody, there was never a class, there was never a professor, there was never a career fair that I attended that had any element of clinical research.
00:01:59
Speaker
um Fast forward to today, you know that might be slightly improved, um but not much change. you know Even still my contemporary colleagues coming into clinical research somehow or another kind of you know stumbled upon the opportunity. For me, you know as I kind of fell into my first job as a clinical research coordinator, i think the boxes that were ticked for me when that first opportunity came my way
00:02:34
Speaker
you know broadly, I understood it as something that was going to be involved. Um, was going to allow me to be involved with patients. So there was an element as, um, you know, a young person who at one point aspired to go to medical school, um, and saw my, you know, future somehow or another as a clinician that was very appealing. So being in a healthcare care environment and,
00:03:04
Speaker
you know, interacting with people having, um you know, unmet health care was appealing. The other piece to it was on the, um you know, on the pharma side, it was big business represented big business, um you know, just from the pharmaceutical industry standpoint. um And I also like the idea of being part of something to prove.
00:03:33
Speaker
to prove relative safety, to be part of proving, you know, do ah pharmaceutical companies and the claims that they're making, you know, how's that actually substantiated? So, you know, something I really kind of fell into, but that's what drew me in. And those were still, I think, elements of clinical trials, especially on the side For those of us who work alongside clinicians and are working with patients and facilitating clinical research today, those truths still really remain. um
00:04:09
Speaker
So that was a little bit in terms of, I think, my why. And in pretty short order, you know i at least felt like I had found the career, the industry, the environment, the culture, the mission that was just a match for me.
The Mission-Driven Focus of Healthcare
00:04:25
Speaker
and um you know blink my eyes all these decades later. And um in a lot of ways, what I'm still doing today is exactly what I set out to do that first day you know on the job as a research coordinator.
00:04:39
Speaker
Yeah, and I think with a lot of people, a lot of people in healthcare care are drawn to the fact that it's mission driven or they care about the mission.
Understanding the Drug Development Process
00:04:45
Speaker
But the good thing about healthcare care is almost every facet of it has that mission that we're working towards. So um it's just quite easy to fall in love with your job in that way.
00:04:54
Speaker
But I'd love to hear with clinical research. I mean, you've seen the industry from some different angles. from working at different sites and then being in operations like advocacy, all these different areas. Like what did you learn early about clinical trials and how they actually work in practice that took much longer for, say the broader industry to realize?
00:05:13
Speaker
I think one thing that I learned that I had no appreciation for is generally speaking, how well the process in the United States around drug development actually works. um It's a very structured process. It's highly regulated.
00:05:34
Speaker
um Clinical trials you know really has ultimately the oversight by Health and Human Services and within Health and Human Services, FDA has set forth a very rigorous framework around which um getting drugs, manufacturers getting drugs approved in the United States, whether it's ah a new drug or whether it's a medical device, actually goes through a very rigorous scientific process. And if you look over the history of time, um you know it has served us well from a public health standpoint.
00:06:14
Speaker
Probably a little more controversy in more recent years, especially around COVID, you know the impacts of COVID, vaccine. But I think what everybody you know sometimes loses context is that
Research Community's Role in Public Health
00:06:28
Speaker
In the case of the pandemic, we were in a situation, an unprecedented you know global um health crisis, um unlike any other, at least that you know from a global standpoint, that we had experienced you know over you know decades, if not hundreds of years.
00:06:48
Speaker
And um you know that process was extraordinarily accelerated from that of what the usual process is. but You know, what I really you know learned is that that process, generally speaking, does generally speaking again, protect the human, you know, um or I'm sorry, the the general public. I think of clinical research, the clinical research community as an important extension of public health.
00:07:21
Speaker
um um You know, because even still today, Nikhil, from when I started in research, even to today, um you know the process is um it's long, it's expensive, it's more or less sequential, but the underpinning to clinical trials is always around answering relative questions.
Trust in the U.S. Drug Approval Process
00:07:48
Speaker
And so the questions to be answered in a very rigorous data construct and process construct The underpinning to that is always, is this new drug, this new device, relatively speaking for the targeted patient population, reasonable?
00:08:09
Speaker
Is it reasonable to expose a patient population or the broader general public to this you know new therapy or you know this new medical intervention?
00:08:22
Speaker
Is it reasonable? So it's that kind of risk reward analysis and even though the scope of new interventions and new medications have substantially broadened and increased kind of through the science over the years, you know, that process more often than not works.
00:08:48
Speaker
I think the general population and from a from U.S. s standpoint, I think we do largely set the standard for the world. um But you know generally speaking, i think it is a great privilege that we have um you know all as ultimate consumers of healthcare to generally be able to have trust for that prescription that you know a physician prescribes to us, to walk into a drug store and be able to buy a product off the shelf, um or go into surgery and have you know some device or intervention um you know as part of a procedure or a surgery. I mean, I think it's a, generally speaking, you know we um we've had great benefit from that.
00:09:40
Speaker
Yeah, I think the patient-provider relationship is um really important. and And luckily, as you said, it's been built up by that, by like rigorous standards by the FDA for like medical devices and pharmaceuticals too.
Patient-Centric Approach in Trials
00:09:51
Speaker
But I mean, one thing that you've talked about in other podcasts and just overall in your work was that that same level of personability isn't there and in a clinical trial, or at least from the perspective of the people working in a clinical trial. I mean, patients aren't treated as patients, as you said before, they're treated as like trial subjects. And i think if you think think about that, it seems quite true, at least when you look at research papers, that's how they're defined. And when you look at like how they assign placebos and things like that, it's
00:10:20
Speaker
It's a little bit interesting also where the care goes down, it almost falls into that too. But what are the downstream consequences of like patients being treated as child subjects rather than patients? What does it actually look like and how does that affect health care overall? Well, again, i think generally speaking, we collectively are doing a better job over time in terms of recognizing, celebrating and honoring um individuals who elect to participate in an experimental trial.
00:10:53
Speaker
As you mentioned, you know, in these trials, um you know, sometimes there is a placebo involved, a sugar pill that's involved. Sometimes there's a comparator and already approved, you know, medication, but just because something's already been approved doesn't mean that it does not also come potentially with side effect effects or risk. And then, you know, in all cases with clinical trials, you know, there's there's a new product or a new device that has yet, you know, there's been something yet to be proven, you know, that that that you're trying to get to that answer. um So I think that we're doing a better job with that.
00:11:32
Speaker
However, i think that we, over time and, you know, throughout history, um certain people have been exploited.
00:11:44
Speaker
um you know We certainly know about Tuskegee. Earlier experimentation um you know without the structure around the FDA regulations, institutional review board requirements right around ensuring that people are well informed. and that research is actually a choice and not something that prisoners are subjected to or you know vulnerable patient populations. Because that by fact happened in the past, I do think that generally speaking, society had to correct
00:12:34
Speaker
in you know a pretty extreme way. And so the correction on that was more an orientation around we are going to protect human participants.
00:12:45
Speaker
I think the more modern view and opportunity, at least my view, but I think certainly an opportunity, um we have made strides. Are we perfect?
Integrating Research into Healthcare Systems
00:12:56
Speaker
you know Have we gotten quote unquote there yet? Absolutely not. But there have been improvements that have been made. And I think that in society and healthcare, care even more broadly, you know, that journey towards ensuring that all of us as healthcare care consumers have better health literacy and that we as healthcare care consumers have more choice in our healthcare care and not just being informed with respect to research, but just informed
00:13:30
Speaker
as healthcare consumer. um you know So much of my work um you know within my company, a lot of the purpose behind the founding of this company, but even really going back for the you know nearly 40 years that I've been doing this, has been the recognition that people have a right to know, and we have a responsibility as best as we can to inform people, you don't know what you don't know.
00:13:59
Speaker
And in some cases, particularly even today, rare disease, oncology, you know countless others, in some cases, there is no other alternative for a person. there is There is perhaps not a medication that is actually available that has been FDA approved. The only way that you could get access to it is through a clinical trial. So I think that's the you know important underpinning of the work that you know not only my company is doing, but many others, you know how do we kind of switch that narrative and ensure that we can mainstream access to clinical research just so that people have the option.
00:14:45
Speaker
They have the option to you know learn, and it's not that a physician or that a health system or one individual is the gatekeeper to whether or not you, Nakiel, or your family member may or may not even know you know that there's something else out there.
00:15:04
Speaker
Yeah. And I think that's really interesting. It's also a huge it's a huge and very wide problem. I think we've seen so many startups attacking from different ways. But for Javar, I'd love to hear for your specific approach. I think it's really interesting, like an integrated research organization. That's not something that was currently like ah a huge thing on the market. So you almost invented like a whole new category.
00:15:24
Speaker
And to that extent, like what is the mission, and the purpose behind Jovara and thinking about its products and services? Like what were the first principles that you maybe thought of and the constraints you thought of when designing a service that could work for both pharma and patients and clinicians and all the other stakeholders you have to deal with when working with these large scale clinical trials?
00:15:45
Speaker
Yeah, I think the underpinning to, you know, the the why behind you know building an integrated research organization probably had more to do with just the changing landscape of healthcare in and of itself. I mean, when I entered clinical research, um the healthcare care you know field was very, very different.
00:16:10
Speaker
um More often than not, physicians were independent operators. You know, you had some physicians who were part of academic medical centers and you had some physicians that, you know, were part of a health system, but the vast majority of physicians were independent. And again, you know, in 2026, that is radically different. I think it's somewhere in the neighborhood of 75% of U.S. providers now are actually employed by systems.
Leveraging Technology for Patient Selection
00:16:45
Speaker
So, you know, the the access to research, we really felt like there needed to be a new model that was built really from the ground up that was equipped from a regulatory, from a legal standpoint, from a service orientation, from a technology enablement, that clinical research actually really starts at the healthcare institution level.
00:17:15
Speaker
And so that you're building the partnership directly with the healthcare care organization and that healthcare care organization in turn is employing physicians, um, or they are partnering with community based physicians and they're providing just a lot of support services to physicians. So the physicians aren't acting as independent operators.
00:17:41
Speaker
So i think that's the that's probably one of the most important kind of differentiation points for us. What this really means from a pharma standpoint is that rather than you know working in isolation with you know a physician here or there, when we have a relationship with their employer or their affiliated healthcare care organization, that work is being supported and we're basically able to build the reach across a much broader enterprise. you know
00:18:16
Speaker
And the way that we're doing that is by having access to the electronic health records. There are special regulatory provisions for the use of research that actually allow a business associate to work with a health care system for purposes of identifying research opportunities for active patients.
00:18:41
Speaker
And that's really what we're, you know, that's really what we're leveraging. So from a pharma company standpoint, you know, these trials are so complex, patient populations are so targeted that going into a small physician practice where a physician might be treating or seeing or following only 3000 patients,
00:19:05
Speaker
even today with a diabetes study, for example, you know, which is a, you know, something unfortunately too many, um you know, people have diabetes, but the types of trials that are being run to kill are so specific. It's not just any diabetic patient. They're very, very specific patient populations. So unless you really have a much larger access to a much broader you know, kind of data set around that electronic health record, um it's going to be very, very difficult to be able to adequately contribute, you know, and enroll and contribute a sufficient number of patients, um you know, for trial delivery.
00:19:54
Speaker
So that's why we're partnering with healthcare systems. Healthcare care systems are giving us access in an appropriate way to the electronic health record. together with pharma, then we can basically look and see, does this patient population across a hundred thousand patients or 3 million patients, what's the prevalence of this patient population? And then how can we best organize a services approach and engagement approach to best reach, you know, as many of those people as we possibly can.
00:20:29
Speaker
and With that, i mean, you have the EHR data from hospitals, but I think a huge issue of that is actually getting to patients. And is that something Javara covers themselves? And if so, like, what does that process look like?
00:20:42
Speaker
Yeah, it's a very um complicated process. So it really starts with, um you know, getting the as much information as we can get about a prospective trial as early as possible. So generally speaking, you know when we first learn from pharma about a prospective trial, oftentimes that full research protocol has not been finalized. you know It's still in draft.
00:21:12
Speaker
And so um you know there's generally an outline in terms of the thoughts around the targeted patient population, but some of the specifics around um you know the the exacts, around the defining the patient population are not fully baked for us.
00:21:32
Speaker
you know Ultimately, in in our experience right now, Nikhil, we're seeing in protocols, again, depends on the patient population, but in some cases, you know in more complex diseases, um you know we're seeing sometimes 50 to 60 specific inclusion exclusion criteria.
00:21:53
Speaker
So we're trying to get as much information as we can as early as we possibly can. And it does go through a pretty complicated you know process. I mean, there's a hyper focus in terms of that last mile about how you actually, once you've identified the patient, you know, get them through the trial. I don't know that there's always as much emphasis um or discussion around what it actually takes to get to that point. I mean, in our case, we have highly skilled teams of people that are assessing that. And so some of that assessment is coming from, you know, just what we have done in the past, what we have known in the past, similar types of patient populations, you know, what are some of the assumptions that we are making?
Challenges in Patient Recruitment
00:22:39
Speaker
We are doing a preliminary assessment across an electronic health record. Now, you know, health records for the most part, electronic health records still do not have the capability to hone in on those 50 to 60 inclusion exclusion criteria.
00:22:57
Speaker
They can do a pretty good job perhaps of slicing and dicing and maybe you know pulling out the top 10 criteria. So beyond electronic health records, we're also leveraging technologies that are really helping us with the more minute kind of matching on that inclusion exclusion.
00:23:19
Speaker
So again, it's it's a process and, you know, over a period of time, generally speaking, we're getting more clarity on ultimately what that final research project is going to look like in terms of a ultimate defined patient population and not just the inclusion exclusion, but what's actually going to be required of the patients, you know, during the trial, um you know, are they going to have to have um you know highly specialized ah diagnostic testing, what's going to be the frequency in terms of the interactions you know that we're seeing them, how does that flow within their normal course of standard of care for that particular disease or condition, how many more encounters, how much data are we going to be collecting. So again, it's a very you know complicated you know process. Again, i think that where innovation is really you know driving us towards is streamlining you know all of that.
00:24:27
Speaker
And um you know there's good progress that's being made in the broader marketplace in terms of those tools that are helping that process. But it's still a highly intensive you know people. There's there's definitely from the standpoint of identifying a prospective trial, ultimately to that being a fit.
00:24:49
Speaker
And what I would say, the conversion of a prospective trial participant to an active, um you know, patient trial participant, there's an art and a science that's that' that's going into that. And it's still a very, you know, high touch, um you know,
00:25:10
Speaker
process and I don't anticipate, i mean, even with ai and a lot of other rapid advancement, we will continue to make improvements, but I don't anticipate that that is going to have a radical change, you know, here, even within the next, you know, five to 10 years.
Selling Innovation in Healthcare
00:25:31
Speaker
and And I think that's really, really interesting. i mean you guys have built technologies from the ground up to do a problem that's when people are spending billions of dollars to solve the idea of like patient recruitment. But something that I've realized about health care is that there's often like a resistance to change.
00:25:45
Speaker
um Big pharma is super hard to sell to. As you know, hospitals are super hard to get in touch with. There's a huge I mean, the bureaucracy is there for better or worse, but also you kind of have to prove yourself. us the Same way you're proving clinical research, you have to prove yourself to the people you're selling to and part trying to partner with.
00:26:02
Speaker
So what does that look like? The system is super entrenched. It's been like this for decades since the FDA has been founded. And when you're trying to offer your product, what does that process look like? And how have you described your value prop to hospitals, biotechs, pharma companies to present the urgency of your solution and what they can value and offer to them?
00:26:23
Speaker
Well, first of all, it's it's important to understand the value proposition is different to the various stakeholders that you just mentioned. so um, I believe strongly that the greatest opportunity that we have collectively is to better articulate, not only articulate, but bring forth the data that demonstrates exactly what that value proposition is So from a pharma standpoint, I think the value proposition to pharma ultimately around an integrated research organization, you know working in concert with health systems is around efficiency.
00:27:06
Speaker
And um you know it's just basically speed. The faster that we can identify and recruit and convert a prospective patient population into all participants, the better.
00:27:23
Speaker
um Because from a pharma standpoint, it is all about you know time. And um the more that we can condense time around that process, the better. So ultimately for pharma, you know the value proposition is around how quickly you can get started How quickly you can get that last patient in, not so much the first patient in, but the very last patient in. um And how clean and accurate and reliable is that data?
00:27:56
Speaker
Like data reliability, again, is what it all you know comes down to. So that's the value proposition from a pharma standpoint. Every day that goes by, especially if you look at potentially a blockbuster drug, for every additional day that a pharma company is waiting for their trial to be completely enrolled, you know it can be millions of dollars, million dollar, millions of dollars, you know in case if if you look at maybe even some of the large GLP-1, these multi-billion dollar drugs.
00:28:33
Speaker
So that's the value proposition you know for pharma. I think from a Javara standpoint and for our contemporaries, you know the more standardization around that process, that's helpful.
00:28:47
Speaker
So rather than working with 100 different vendors, 100 different investigators, doing things slightly differently, that comes at a high cost to pharma, right? Just managing through that. So the standardization, I think, is another important you know value proposition.
00:29:06
Speaker
From a healthcare standpoint, that's the one that I actually find to be so gratifying um and probably what I believe is going to be Jabara's legacy.
Benefits of Clinical Research Integration
00:29:17
Speaker
We'll see how this plays out in the years to come. But I think um you know from a health system standpoint, enabling the scalability of the clinical research offering across the broader enterprise stands to do some important things. Number one, we know by fact people who are enrolled in clinical trials have a better patient experience than for patients within a system not enrolled in a clinical trial.
00:29:51
Speaker
Okay, people are getting concierge care if you're in a clinical trial. um so there are so many more touch points they are a volunteer it's important that we're getting clean data and in doing so you know you really are giving people i think you know the highest touch care delivery experience that there is um because they're a volunteer and you have to make the process as delightful for them as it possibly can be there's a huge
00:30:23
Speaker
learning opportunity for people to become more engaged um and more educated about their disease condition and you know even other comorbidities that they might have.
00:30:35
Speaker
So the patient experience is a hugely important piece. We survey we survey patients. And so the value proposition to health systems is that ongoing feedback about what their patient experience is.
00:30:50
Speaker
um The second you know um piece to this from a value proposition standpoint is the physician and the provider experience. you know One of the crisis points that we have in the US is around physician burden, physician burnout, and especially in rural communities, we have physician shortages.
00:31:14
Speaker
So clinical trials in in our experience actually is something that can enhance the provider's just career journey. You know, it's it's it's, they're part of now something that's a little bit bigger. It can connect them from a scientific contribution standpoint. um You know, they didn't elect to go into academia. They elected to go into community care. but it does put them in this you know kind of new realm um from a from a professional standpoint. There's economic advantages obviously you know that come with this.
00:31:54
Speaker
um And I think the you know the creating a new revenue stream for a health system or for the providers is
Involving Clinicians in Research
00:32:05
Speaker
an advantage. But last, but certainly not least, I do think that there is substantial benefit to the healthcare care system and to the broader, just the broader ecosystem that clinical research actually can also reduce cost of care.
00:32:22
Speaker
um You know, if you think about a high risk cardiovascular patient that's enrolled in a clinical trial over a five year period of time, that individual's medication is being provided for through the clinical trial for that particular disease or condition that's under study. All the diagnostic testing and following that patient for that chronic disease is being covered by, you know, the clinical trial. So the cumulative effect and impact from even an economic standpoint to the health system is substantial.
00:33:02
Speaker
And I think um it's are really exciting. Also, especially with clinicians, I know they're kind of, they're often kind of almost left out of the like out of the bigger picture because you have big health hospitals and pharma companies and clinicians are there on the ground doing a lot of the work, but they're not the ones in discussions around this. And I think from you guys, your guys' perspective, I know you guys have heard a lot of and worked with a lot of new clinicians, new physicians that are new to being investigators.
00:33:30
Speaker
And what does that process look like, getting them adjusted to research? mean, yeah, they're not in academia, so they still understand how research goes, but that's not their job per se. um what do they What do you have to teach them and what does that process look like and what does that end up resulting in when you have clinicians actively involved and excited about working in research?
00:33:50
Speaker
Yeah, I think that, well, um a couple of points to this. I'm going to say from our experience, it is that journey is improving over time. I do think that putting a lot of structure into ensuring that the physician education and onboarding experience of becoming a prospective research investigator you know, whether it's a principal investigator or a sub-investigator, it is a process. I mean, the industry desperately needs, we desperately need more physicians participating in research. We have a lot of established, experienced investigators that are aging out and retiring, and we have not been replacing, you know, kind of new talent at the same pace as we have physicians who have been, you know, researchers.
00:34:46
Speaker
that are leaving. um And, you know, part of the conundrum is around risk. um And, you know, industry, the pharmaceutical industry, you know, like health systems and like, you know, many, many of us and many other industries, you know, it really is about risk mitigation.
00:35:07
Speaker
So, um you know, for industry to take on an unproven physician is a new investigator, um is a steep hill to climb.
00:35:22
Speaker
Now, from a Javara standpoint, when we were founded eight years ago, that was a really tall order. For the most part, the physicians that we were working with in the earliest days had great aspirations.
00:35:37
Speaker
Um, to be involved in research, but they did not have experience. Maybe they'd had a little bit of exposure during their training, but you know, they didn't have really industry experience, um, with clinical trials. Um, so that was more challenging. Um, and fortunately, you know, every once in a while, whether it was a big pharmaceutical company or midsize or a small biotech, every once in a while, you'd come across a decision maker who would kind of see um you know that that they needed to be a partner for the future. And you know almost kind of in an ad hoc you know highly specialized case, they would bring a new they would allow us to bring a new investigator forward. I think over the years, as we have been able to successfully demonstrate um that onboarding, bringing more structure around how we're training,
00:36:34
Speaker
these investigators, whether it's just you know good clinical practice training or kind of our own bespoke training. I think the other thing that's really helpful and important from a broader standpoint, it's see one, do one, teach one.
00:36:49
Speaker
So, you know in a in a pretty mindful way, pairing a new physician who aspires to be an investigator with an experienced physician who is an an investigator, has proven to also be very, very helpful.
00:37:06
Speaker
um And you know that it's more likely that you bring a new physician in as a sub-investigator in that secondary role. You pair them with a seasoned, um experienced investigator. And you know I think that's that's proving to be um a good pathway. I'm really proud of the fact, you know at least in over the Javara journey, you know we have about 150 physicians that not so long ago had never been involved in the clinical trial.
00:37:35
Speaker
um So it is it is possible. um And then I would just say kind of from a pitfall standpoint, Nikhil, I would say it's very important you know for anybody in your audience who you know might be in a position to affect change or even focus you know on this area. um you know I think it really is about appropriately educating a physician about oversight responsibilities. I mean, ultimately within the US, the FDA still has the view that these clinical trials have the oversight responsibility by one investigator.
00:38:19
Speaker
um I think there's, again, you know there's no handbook that's out there that tells you exactly what it is the physician has to do um versus what they're supervising.
Javara's Role in Improving Health Outcomes
00:38:32
Speaker
And I think in some cases, you know, those expectations have not really been clear to a physician. But at the end of the day, the physician does have the responsibility ultimately for the oversight, you know, of the safety um and, you know, the safety of the patient volunteer and ensuring that the data that's been collected
00:38:58
Speaker
is truthful, you know, and it's accurate and it's complete. And if something happened and it wasn't fully, information was not fully collected or protocol was not fully adhered to, that it's been reported and well documented.
00:39:14
Speaker
So, you know, the responsibility of the investigators, I think, whether it's a system or it's a company like Tavara or whoever it might be, a pharmaceutical company directly,
00:39:27
Speaker
um You don't want a shortcut sugarcoat in a way to a physician ultimately you know what what that responsibility carries.
00:39:38
Speaker
Right. and i think it's going to be as you have this mentorship model training clinicians up and I think we'll see more and more clinicians want to be part of something greater as you mentioned. and That's what it kind of all is I mean, Javar is part of something greater, which is the clinical trials process, is part of getting drugs to people and then of course,
00:39:55
Speaker
so many pharma companies and insurance companies is this huge Patrick and healthcare and hopefully in the next few years, Javara will be a part of like kind of integrating and interroping all of those different
Closing Remarks and Additional Content
00:40:05
Speaker
functions. But I really appreciated the kind of hearing more about Javara today.
00:40:09
Speaker
it's so It's a difficult problem clinical trials and it's a huge one too. the potential to save like millions of lives, billions of dollars, but also it's expensive to do so also. But um it's been really interesting to hear your perspective on anything. So thank you again, Jennifer, for coming on the podcast today. really appreciated your time.
00:40:27
Speaker
Well, thank you, Nikhil. And, you know, keep doing this important work that you're, you know, doing and leading and that curiosity will serve you and all of us very well in the future.
00:40:41
Speaker
Thanks for listening to The Healthcare Theory. Every Tuesday, expect a new episode on the platform of your choice. You can find us on Spotify, Apple Music, YouTube, any streaming platform you can imagine.
00:40:53
Speaker
We'll also be posting more short-form educational content on Instagram and TikTok. And if you really want to learn more about what's gone wrong with healthcare care and how you can help, check out our blog at thehealthcaretheory.org.
00:41:05
Speaker
Repeat, thehealthcaretheory.org. Again, i appreciate you tuning in I hope to see you again soon.